Investor Ideas Potcasts #513 Cannabis News and Stocks on the Move; (TSXV: FLWR) (OTC: MJNA) (OTCQB: CTGL) (TSX: AVCN)
Delta, Kelowna, BC - January 6, 2021 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Investor Ideas Potcasts #513 Cannabis News and Stocks on the Move; (TSXV: FLWR) (OTC: MJNA) (OTCQB: CTGL) (TSX: AVCN)
Today's podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today's podcast we will be looking at a few public company announcements.
North America's first research and development facility dedicated to advancing cannabis cultivation techniques and systems has been completed by The Flowr Corporation (TSXV: FLWR) and Hawthorne Canada Limited. Hawthorne is a subsidiary of the Hawthorne Gardening Company division of The Scotts Miracle-Gro Company (NYSE:SMG). Scotts Miracle-Gro is the world's leading marketer of branded consumer lawn and garden products and indoor growing solutions. Flowr cultivates and sells premium cannabis to medical and adult-use markets in Canada, Europe and Australia.
Located on Flowr's cultivation campus in Kelowna, British Columbia, Canada, the R&D Center includes state-of-the-art laboratories, indoor grow suites, and training areas in a single building. Flowr will test cultivation systems and techniques using Hawthorne's advanced lighting, fertilization and irrigation systems, growing mediums, and research protocols. In addition, Flowr intends to focus its own research on cannabis genetics and integrated growing systems in line with its goal of delivering premium quality cannabis products through highly efficient cultivation.
"We built Hawthorne to help cultivators of all sizes grow quality plants with high levels of efficiency and consistency. Completing the industry's only dedicated R&D facility gives us a distinct advantage. We will leverage Flowr's cultivation expertise and our technical capabilities into real world testing and results that will make a difference to growers," said Chris Hagedorn, SVP & General Manager of Hawthorne Gardening. "We are proud of this collaboration with Flowr, a leading international cannabis company, with extensive growing experience indoors, in greenhouses and at-scale outdoors. Flowr is also one of a few companies that have had experience growing diverse genetics in different countries. We believe this experience will benefit our companies and the growers we serve."
"The completion of the R&D Center brings our work with Hawthorne fully to life and will help keep both companies on the leading edge of cannabis cultivation for years to come," commented Lance Emanuel, President and Interim Chief Executive Officer of Flowr. "Operationalizing the R&D Center is a major accomplishment for our organization and strengthens our competitive advantage in cultivation. We believe the long-term success of Flowr will be rooted in our ability to maximize the cannabinoid and terpene expression of genetics without sacrificing yield. The work we will do at the R&D Center will help us build upon the success we've had producing high quality, premium cannabis like our award-winning, flagship-strain BC Pink Kush beloved by budtenders and consumers throughout Canada. Leveraging our work at the R&D Center will be imperative to our eventual entry into the United States once federally permissible by law."
The R&D Center is the centerpiece of a strategic R&D partnership formed by Flowr and Hawthorne in March 2018. It brings two of the world's leading experts together to be at the forefront of cannabis cultivation. The operations will be led by Dr. Deron Caplan, the first person in North America to earn a PhD focused on cannabis cultivation and production. Dr. Caplan was awarded his doctorate by the University of Guelph in August 2018 and is Flowr's Director of Research and Development. The R&D Center will be staffed by Flowr's scientists, five of whom have PhDs in various plant biology, plant genetics and plant biochemistry disciplines. Hawthorne R&D will lead the research design and methodology.
All requisite licensing from Health Canada has been obtained by Flowr and the expectation is that the R&D Center will be operating at full capacity in Spring 2021. Research has already begun conducting growing trials at scale using Hawthorne products.
Medical Marijuana, Inc. (OTC: MJNA) announced that its subsidiary HempMeds® has launched its first-ever products containing cannabigerol (CBG) and cannabinol (CBN) as part of the Company's recently updated brand strategy.
"When we founded HempMeds a decade ago, we were helping to create the entire CBD category. Since then, CBD has become the booming industry that we expected and acceptance for cannabinoids has come an incredibly long way in the last few years," said HempMeds® Co-Founder Michelle Sides. "While our flagship RSHO products remain popular, we recognized it was time to expand alongside the industry and broaden our offerings as part of the company's exciting new direction. We are confident that consumers will be excited about our new CBG and CBN products."
Each 12-ounce bottle of HempMeds®' RSHO® Calm Support is formulated to promote overall relaxation with 300 mg of CBN, 2,000 mg of CBD and 300 mg of Piperine, naturally derived from black pepper, to increase bioavailability.
For those looking for an additional boost of focus, each 12-ounce bottle of RSHO® Focus Support offers 1,500 mg of CBD, 1,500 mg of CBG and 300 mg of Piperine.
"It is amazing to think that there are over 100 lesser-known minor cannabinoids in the cannabis plant, each with its own potential benefits. With minor cannabinoids like CBG and CBN growing in popularity, they will likely take over more and more of the expected $47.2 billion global cannabis market. We look forward to continuing to expand and evolve our offerings in response to consumer demand, starting with these new products," said HempMeds® CEO Raul Elizalde.
On December 30, 2020, Cannovation Center Israel Ltd. won Israeli Government Ministry of Economy grant to acquire 10,000 square meters (2.5 acres) of industrial land to build the Cannovation Center Israel at the Biopharma Park in Yeruham.
The Cannovation Center Israel is a unique platform that includes factories for the production of medical cannabis, botanicals, CBD, hemp, supplements, food, and cosmetic products; laboratories for quality assurance, research, development, and clinical trials; a logistics, distribution, import and export center; business development strategy services.
Citrine Global, Corp. (OTCQB: CTGL) operates in Israel through its wholly owned subsidiary, CTGL - Citrine Global Israel Ltd. ("Citrine Global Israel"), which focuses on Israeli technologies in the fields of healthcare, wellness, foodtech and medical cannabis.
Cannovation Center Israel Ltd. is 60%-owned by Citrine Global Israel Ltd. and Citrine Global Group views the establishment of the Cannovation Center Israel as a national project backed by grants and support from the Israeli government and the Yeruham local council, and is aiming to create an ecosystem and collaborations between companies, entrepreneurs, universities and partners from Israel and around the world.
Ora Elharar Soffer, CEO, Citrine Global Corp.: "We are proud to be the ones to establish the first operational innovation center of its kind for cannabis in the Biopharma Park in Yeruham with the support of the Israeli government and Yeruham Local Council and take part in the realization of Tal Ohana's vision to turn Yeruham into the capital of medical cannabis. The Cannovation Center Israel will provide a comprehensive operational solution tailored to the requirements of the cannabis and botanical industry and is an important milestone that combines production, operations, technologies, and business development to leverage local and international collaborations. According to our strategy, we plan to build additional operational innovation centers working in this business model around the world."
Tal Ohana, Mayor of Yeruham: "We have been working with Ora Elharar Soffer and the Citrine Global Group and welcome the establishment of the innovative Cannovation Center Israel in the Biopharma Park in Yeruham. Our vision to turn Yeruham into the medical cannabis capital, through the Green-Negev project which I have been leading in the last few years, is becoming a reality. We receive support from the Israeli government and leading companies and entrepreneurs. In the last year, we have established a start-up incubator for cannabis technologies with the assistance of the Innovation Authority and in partnership with the pharmaceutical company Perrigo, which has a factory in Yeruham, and with Israeli Cannabis Company BOL. The incubator is already active, and the expected volume of investments is NIS 150 million for the operation of the incubator in the coming years. In addition, we received approval from the Ministry of Economy to allocate land and support factories' construction, which includes a 30% return on investment in the construction of the factory, a subsidized industrial area, reduced corporate tax, subsidy for senior employees' salaries, and more."
Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announced that the Company has entered into a master services agreement with the University Health Network for projects to be performed by Dr. Peter Carlen as the principal investigator related to epilepsy. Additionally, the company has completed the technical transfer and first pharmaceutical pilot production of its epilepsy drug candidate at Altea Farmaceutica S.A. in Bogota, Colombia, a major step required for the final preparation for its registration and commercialization in South America.
The epilepsy research collaboration is lead by Dr. Peter Carlen, who is a Senior Scientist at the Krembil Research Institute at UHN and a world-renowned researcher in the field of epilepsy. Dr. Carlen's laboratory will be analyzing Avicanna's RHO Phyto and pharmaceutical cannabinoid-based products for their efficacy in the treatment of seizures.
The partnership will also co-develop a high throughput electrophysiological testing system for the evaluation of multiple cannabinoid ratios and in combination with standard epileptic drugs. In addition, the system will examine standard anti-seizure drugs for their efficacy in the model and determine the potential synergistic value of adjunctive cannabinoids, and cannabinoids as monotherapy in treating seizures in this in vitro setting.
Dr. Peter Carlen commented: "The Carlen lab is very pleased to research the relationships between the premium medicinal cannabinoid products of Avicanna and their effects on epilepsy. Also, in collaboration with Avicanna, we are developing a high-throughput platform to assess these interactions. We think that medical cannabinoids will have a major impact on brain health, particularly as we gain greater understanding of their effects on brain function in health and disease."
The services to be performed under the Master Services Agreement will be provided on an exclusive basis and Dr. Carlen's laboratory has agreed to not conduct testing on any formulations or products similar to the Products for a period of two (2) years. All intellectual property created under the Master Services Agreement will remain the sole property of Avicanna. The research collaboration is further expanded to include electrophysiological studies of medical cannabinoids on 3D human cerebral organoids and neuroglial cultures with the support of a two-year Mitacs Accelerate program grant.
Avicanna also completed its first pharmaceutical level production of its first epilepsy drug candidate under GMP and ICH guidelines which are necessary for sanitary drug registration. The formulation developed by Avicanna includes active pharmaceutical ingredients which are cannabinoids produced by Avicanna's subsidiary Santa Marta Golden Hemp S.A.S. The final GMP manufacturing took place at Avicanna's exclusive manufacturing partner's, Altea's, facility in Bogota, which is a Health Canada and ANVISA (Brazil) approved GMP facility. The completion of this pharmaceutical production now allows Avicanna to proceed with drug registrations for epilepsy across several markets in South America including Colombia and Brazil.
Aras Azadian, CEO of Avicanna, commented: "We are pleased to demonstrate our dedication to world-class research and to take this stride in our epilepsy research program with a leading Canadian research institute and Dr. Carlen. This multi-level partnership will help to further study our current medical cannabis and pharmaceutical products, and will support the development and increase the depth of our pharmaceutical pipeline. Additionally, the completion of our first pharmaceutical production marks a milestone event in our drug development plans and highlights our capabilities to scale our drug formulations from bench top to industrial manufacturing."
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining the AI Eye.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Cannabis Social Media
Download our Mobile App for iPhone and Android